-
EP4106743
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4106743
| EP4106743 - AZELAIC ACID ESTERS IN THE TREATMENT OR PREVENTION OF DYSLIPIDEMIA AND ASSOCIATED CONDITIONS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 25.11.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 27.08.2021 | Most recent event Tooltip | 25.06.2024 | The date on which the examining division becomes responsible, has been established | 25.06.2024 | Amendment by applicant | Applicant(s) | For all designated states New Frontier Labs, LLC 900 NE Loop 410, Suite D-119 San Antonio, TX 78209-1403 / US | [2022/52] | Inventor(s) | 01 /
STREEPER, Robert T. 7738 Apple Green Road San Antonio, TX 78240 / US | 02 /
IZBICKA, Elzbieta 7738 Apple Green Road San Antonio, TX 78240 / US | [2022/52] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2022/52] | Application number, filing date | 21756267.7 | 19.02.2021 | [2022/52] | WO2021IB51451 | Priority number, date | US202062978785P | 19.02.2020 Original published format: US 202062978785 P | [2022/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021165924 | Date: | 26.08.2021 | Language: | EN | [2021/34] | Type: | A1 Application with search report | No.: | EP4106743 | Date: | 28.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.08.2021 takes the place of the publication of the European patent application. | [2022/52] | Search report(s) | International search report - published on: | KR | 26.08.2021 | (Supplementary) European search report - dispatched on: | EP | 07.12.2023 | Classification | IPC: | A61K31/225, A61K45/06, A61P3/06, A61K31/155, A61K31/192, A61K31/22, A61K31/23, A61K31/365, A61K31/366, A61K31/40, A61K31/404, A61K31/4439, A61K31/455, A61K31/505, A61K31/573, A61K38/22, A61K38/26, A61K9/00, A61P3/10 | [2024/02] | CPC: |
A61P3/10 (EP,IL,US);
A61K31/225 (EP,IL,KR,US);
A61K31/155 (EP);
A61K31/192 (EP);
A61K31/22 (EP);
A61K31/23 (EP);
A61K31/365 (EP);
A61K31/366 (EP);
A61K31/40 (EP);
A61K31/404 (EP);
A61K31/4439 (EP);
A61K31/455 (EP);
A61K31/505 (EP);
A61K31/573 (EP);
A61K38/22 (EP);
A61K38/26 (EP);
A61K45/06 (KR);
A61K9/0019 (EP,IL);
| C-Set: |
A61K31/155, A61K2300/00 (EP);
A61K31/192, A61K2300/00 (EP);
A61K31/22, A61K2300/00 (EP);
A61K31/23, A61K2300/00 (EP);
A61K31/365, A61K2300/00 (EP);
A61K31/366, A61K2300/00 (EP);
A61K31/404, A61K2300/00 (EP);
A61K31/40, A61K2300/00 (EP);
A61K31/4439, A61K2300/00 (EP);
A61K31/455, A61K2300/00 (EP);
A61K31/505, A61K2300/00 (EP);
A61K31/573, A61K2300/00 (EP); |
| Former IPC [2022/52] | A61K31/225, A61K45/06, A61P3/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/52] | Title | German: | AZELAINSÄURE-ESTER ZUR BEHANDLUNG ODER VORBEUGUNG VON DYSLIPIDÄMIE UND DAMIT VERBUNDENEN ZUSTÄNDEN | [2022/52] | English: | AZELAIC ACID ESTERS IN THE TREATMENT OR PREVENTION OF DYSLIPIDEMIA AND ASSOCIATED CONDITIONS | [2022/52] | French: | ESTERS D'ACIDE AZÉLAÏQUE DANS LE TRAITEMENT OU LA PRÉVENTION DE LA DYSLIPIDÉMIE ET DE PATHOLOGIES ASSOCIÉES | [2022/52] | Entry into regional phase | 19.09.2022 | National basic fee paid | 19.09.2022 | Search fee paid | 19.09.2022 | Designation fee(s) paid | 19.09.2022 | Examination fee paid | Examination procedure | 19.09.2022 | Examination requested [2022/52] | 25.06.2024 | Amendment by applicant (claims and/or description) | 25.06.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 22.02.2023 | Renewal fee patent year 03 | 22.02.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [ ] - No further relevant documents disclosed | International search | [Y]WO2017184767 (NEW FRONTIER LABS LLC [US]) [Y] 37,38,44,45,51,52 * abstract; and paragraph [0036] *; | [Y]US2018207120 (LEE SUNG-JOON [KR], et al) [Y] 37,38,44,45,51,52 * abstract; and paragraphs [0002], [0052], [0053] *; | [A] - Al-Marabeh Sara, Khalil Enam, Khanfar Mohammad, Al-Bakri Amal G., Alzweiri Muhammed, "A prodrug approach to enhance azelaic acid percutaneous availability", Pharmaceutical Development and Technology, US, (20160101), vol. 22, no. 4, ISSN 1083-7450, pages 1 - 9, XP009529918 [A] 37,38,44,45,51,52 * the whole document * DOI: http://dx.doi.org/10.1080/10837450.2016.1200614 | [A] - Muthulakshmi Shanmugam; Saravanan Ramalingam, "Efficacy of azelaic acid on hepatic key enzymes of carbohydrate metabolism in high fat diet induced type 2 diabetic mice", BIOCHIMIE, FR, (20130208), vol. 95, no. 6, doi:10.1016/j.biochi.2013.01.018, ISSN 0300-9084, pages 1239 - 1244, XP028593691 [A] 37,38,44,45,51,52 * the whole document * DOI: http://dx.doi.org/10.1016/j.biochi.2013.01.018 | [A] - Muthulakshmi Shanmugam; Chakrabarti Alok K.; Mukherjee Sanjay, "Gene expression profile of high-fat diet-fed C57BL/6J mice: in search of potential role of azelaic acid", JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, NL, (20150111), vol. 71, no. 1, doi:10.1007/s13105-014-0376-6, ISSN 1138-7548, pages 29 - 42, XP035454906 [A] 37,38,44,45,51,52 * the whole document * DOI: http://dx.doi.org/10.1007/s13105-014-0376-6 | [PX] - Streeper Robert T., Louden Christopher, Izbicka Elzbieta, "Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects", In Vivo, GR, (20200101), vol. 34, no. 3, doi:10.21873/invivo.11890, ISSN 0258-851X, pages 1173 - 1186, XP055839472 [PX] 37,38,44,45,51,52 * the whole document * DOI: http://dx.doi.org/10.21873/invivo.11890 |